$2125 | SAVE $375 | Single User
$4250 | SAVE $750 | Site License
$6375 | SAVE $1,125 | Enterprise License

Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
[Published by Global Data]

Published by Global Data: 29 Jul 2016 | 27240 | In Stock
Related Topics: Breast Cancer , Cancer , Clinical Trials

Introduction

Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016" provides an overview of Metastatic Breast Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Breast Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
for Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016 [Published by Global Data]

  • Table of Contents

    Table of Contents 2

    List of Tables 4

    List of Figures 5

    Report Guidance 6

    Clinical Trials by Region 7

    Clinical Trials and Average Enrollment by Country 8

    Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

    Top Five Countries Contributing to Clinical Trials in Europe 11

    Top Countries Contributing to Clinical Trials in North America 12

    Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

    Top Five Countries Contributing to Clinical Trials in Central and South America 14

    Clinical Trials by G7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials 15

    Clinical Trials by Phase in G7 Countries 16

    Clinical Trials in G7 Countries by Trial Status 17

    Clinical Trials by E7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials 18

    Clinical Trials by Phase in E7 Countries 19

    Clinical Trials in E7 Countries by Trial Status 20

    Clinical Trials by Phase 21

    In Progress Trials by Phase 22

    Clinical Trials by Trial Status 23

    Clinical Trials by End Point Status 24

    Subjects Recruited Over a Period of Time 25

    Clinical Trials by Sponsor Type 26

    Prominent Sponsors 27

    Top Companies Participating in Metastatic Breast Cancer Therapeutics Clinical Trials 28

    Prominent Drugs 29

    Latest Clinical Trials News on Metastatic Breast Cancer 30

    Jul 13, 2016: Penn preclinical study outlines cardiovascular side effects of breast cancer drug 30

    Jun 22, 2016: Prima BioMed Announces First Safety, Pharmacokinetics and Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321 30

    Jun 14, 2016: Cascadian Therapeutics Reports Topline ONT-380 "Triplet" Data and Outlines Key Development Strategies 31

    Jun 06, 2016: Calithera Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at the American Society of Clinical Oncology Annual Meeting 32

    Jun 05, 2016: Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO 32

    Jun 03, 2016: Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology Annual Meeting 33

    Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy 34

    Jun 02, 2016: Corcept Therapeutics Provides Update On Mifepristone Cortisol Modulator Program 35

    May 31, 2016: City of Hope Presents Data on Veliparib at The American Society of Clinical Oncology’s Annual Meeting 36

    May 27, 2016: Astrazeneca's Faslodex Met Primary Endpoint In First-Line Treatment Of Advanced Breast Cancer 37

    May 18, 2016: Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting 37

    May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO 37

    May 18, 2016: Merrimack to Present Data on MM-302 at the 2016 American Society of Clinical Oncology Annual Meeting 38

    May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 38

    May 18, 2016: Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of HER2-positive metastatic breast cancer patients 39

    May 17, 2016: Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series 40

    Clinical Trial Profile Snapshots 41

    Appendix 1886

    Abbreviations 1886

    Definitions 1886

    Research Methodology 1887

    Secondary Research 1887

    About GlobalData 1888

    Contact Us 1888

    Disclaimer 1888

    Source 1889

List Of Tables
in Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016 [Published by Global Data]

List of Tables

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region, 2016* 7

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13

Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14

Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase, 2016* 21

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List Of Figures, Charts and Diagrams
in Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016 [Published by Global Data]

List of Figures

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016* 7

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13

Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14

Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

GlobalData Methodology 1887

Additional Details

Publisher

Global Data

Publisher Information

Reference

27240 | GDHC3617CTIDB

Number of Pages

1889

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $591 (normally
USD $695)
More Info

This report is published by Global Data

Download Free Report Summary PDF

Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...